West Pharmaceutical Services reported higher second-quarter 2026 sales and earnings, raised its full-year 2026 net sales guidance to between US$3.345 billion and US$3.380 billion with organic growth now expected at 10% to 11%, up from a prior 7% to 9%, and completed US$454.28 million in share repurchases under its February 2026 buyback program. The company also issued third-quarter revenue guidance, highlighted momentum in higher-value Proprietary Products for biologics and biosimilars, and affirmed a US$0.22 quarterly dividend. The updated outlook reinforces the investment narrative centered on sustained demand for high-value components used in biologics, biosimilars, and GLP-1 therapies, though risks remain around potential demand shifts or pricing pressure.
West Pharmaceutical Services IncRaised 2026 revenue guidance and completed share repurchases, reinforcing positive outlook.